藤黄健骨丸联合洛索洛芬钠治疗膝骨关节炎的临床研究
|
摘要
目的探讨藤黄健骨联合洛索洛芬钠治疗膝骨关节炎的临床疗效和安全性。方法选取2016年6月—2017年6月在河南省洛阳正骨医院诊治膝骨关节炎患者152例,随机分成对照组(76例)和治疗组(76例)两组。对照组患者口服洛索洛芬钠片,1片/次,3次/d;治疗组患者在对照组基础上口服藤黄健骨丸,1丸/次,2次/d。两组患者均连续治疗6周。观察两组患者临床疗效,同时比较治疗前后两组患者骨关节炎指数、KSS评分和15 m行走时间,血清白细胞介素-1β(IL-1β)、软骨寡聚基质蛋白(COMP)和前列腺素E2(PGE2)水平及不良反应。结果治疗后,对照组临床有效率为86.84%,显著低于治疗组的97.37%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者骨关节炎指数和15 m行走时间均显著下降(P<0.05),KSS评分显著升高(P<0.05),且治疗组患者骨关节炎指数、KSS评分和15 m行走时间均明显优于对照组(P<0.05)。治疗后,两组患者血清IL-1β、COMP和PGE2水平均显著下降(P<0.05),且治疗组患者血清IL-1β、COMP和PGE2水平明显低于对照组(P<0.05)。治疗期间,治疗组药物不良反应发生率为2.63%,显著低于对照组的13.16%,两组比较差异具有统计学意义(P<0.05)。结论藤黄健骨联合洛索洛芬钠治疗膝骨关节炎疗效显著、安全性高,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy and safety of Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis. Methods Patients(152 cases) with knee osteoarthritis in Luoyang Orthopedic Hospital of Henan Pprovince from June 2016 to June 2017 were randomly divided into control(76 cases) and treatment(76 cases) groups. Patients in the control group were po administered with Loxoprofen Sodium Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Tenghuang Jiangu Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the osteoarthritis indexes, KSS scores, 15 m walking time, serum IL-1β, COMP and PGE2 levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.84%, which was significantly lower than 97.37% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the osteoarthritis indexes and 15 m walking time in two groups were significantly decreased(P < 0.05), but KSS scores were significantly increased(P < 0.05), and these indicators in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the IL-1β, COMP and PGE2 levels in two groups were significantly decreased(P < 0.05), and the serum IL-1β, COMP and PGE2 levels in the treatment group were significantly lower than those in the control group(P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 2.63%, which was significantly lower than 13.16% in the control group, with significant difference between two groups(P < 0.05). Conclusion Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis has significant curative effect with less adverse reactions, which has a certain clinical application value.
Objective To investigate the clinical efficacy and safety of Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis. Methods Patients(152 cases) with knee osteoarthritis in Luoyang Orthopedic Hospital of Henan Pprovince from June 2016 to June 2017 were randomly divided into control(76 cases) and treatment(76 cases) groups. Patients in the control group were po administered with Loxoprofen Sodium Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Tenghuang Jiangu Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the osteoarthritis indexes, KSS scores, 15 m walking time, serum IL-1β, COMP and PGE2 levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 86.84%, which was significantly lower than 97.37% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the osteoarthritis indexes and 15 m walking time in two groups were significantly decreased(P < 0.05), but KSS scores were significantly increased(P < 0.05), and these indicators in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the IL-1β, COMP and PGE2 levels in two groups were significantly decreased(P < 0.05), and the serum IL-1β, COMP and PGE2 levels in the treatment group were significantly lower than those in the control group(P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 2.63%, which was significantly lower than 13.16% in the control group, with significant difference between two groups(P < 0.05). Conclusion Tenghuang Jiangu Pills combined with loxoprofen sodium in treatment of knee osteoarthritis has significant curative effect with less adverse reactions, which has a certain clinical application value.
引文
[1]吕厚山.髋、膝关节骨性关节炎的研究现状和进展[J].实用老年医学,2001,15(5):229-233.
[2]金立昆,谢利民,李玉彬,等.膝骨关节炎临床症状与X线表现相关性研究[J].中国骨伤,2009,22(3):170-173.
[3]黄李焘.洛索洛芬钠的研究进展[J].社区医学杂志,2015,13(18):73-74.
[4]贡联兵,冯常智.藤黄健骨片的临床应用评价[J].中国医院用药评价与分析,2012,12(11):967-969.
[5]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:852-855.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:48-49.
[7]夏传涛,余方方,方华,等.西安大略和麦克马斯特大学骨关节炎指数量表应用于大骨节病的信度和效度评价[J].中华地方病学杂志,2015,34(4):274-277.
[8]王春生,靳振岭,张子琦,等.新版KSS评分系统的试应用及分析[J].中国矫形外科杂志,2017,25(1):33-37.
[9]吕苏梅,张瑞丽.中老年膝骨关节炎的流行病学研究进展[J].中国老年学,2016,36(16):4133-4135.
[10]刘强,洪加源,胡维界.膝骨性关节炎治疗进展[J].医学综述,2015,21(3):474-476.
[11]周淑琴.新型非甾体抗炎药洛索洛芬钠的研究进展[J].上海医药,2008,29(10):468-469.
[12]杨坤杰,黄敏,唐仕欢.藤黄健骨片“病证-方药-效应”关联性分析[J].中医学报,2016,31(1):109-113.
[13]陈巍,李彬,唐中尧,等.膝骨性关节炎患者关节滑液IL-1β和TNF-α的表达及临床意义[J].广东医学,2010,31(15):1998-2000.
[14]尹战海,张璐,王菁.软骨寡聚基质蛋白在骨关节炎预后判断中的作用[J].陕西医学杂志,2008,37(12):1638-1640.
[15]彭成忠,肖涛.白细胞介素18和前列腺素E2与骨关节炎[J].中国组织工程研究,2006,10(16):117-120.
[2]金立昆,谢利民,李玉彬,等.膝骨关节炎临床症状与X线表现相关性研究[J].中国骨伤,2009,22(3):170-173.
[3]黄李焘.洛索洛芬钠的研究进展[J].社区医学杂志,2015,13(18):73-74.
[4]贡联兵,冯常智.藤黄健骨片的临床应用评价[J].中国医院用药评价与分析,2012,12(11):967-969.
[5]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:852-855.
[6]国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:48-49.
[7]夏传涛,余方方,方华,等.西安大略和麦克马斯特大学骨关节炎指数量表应用于大骨节病的信度和效度评价[J].中华地方病学杂志,2015,34(4):274-277.
[8]王春生,靳振岭,张子琦,等.新版KSS评分系统的试应用及分析[J].中国矫形外科杂志,2017,25(1):33-37.
[9]吕苏梅,张瑞丽.中老年膝骨关节炎的流行病学研究进展[J].中国老年学,2016,36(16):4133-4135.
[10]刘强,洪加源,胡维界.膝骨性关节炎治疗进展[J].医学综述,2015,21(3):474-476.
[11]周淑琴.新型非甾体抗炎药洛索洛芬钠的研究进展[J].上海医药,2008,29(10):468-469.
[12]杨坤杰,黄敏,唐仕欢.藤黄健骨片“病证-方药-效应”关联性分析[J].中医学报,2016,31(1):109-113.
[13]陈巍,李彬,唐中尧,等.膝骨性关节炎患者关节滑液IL-1β和TNF-α的表达及临床意义[J].广东医学,2010,31(15):1998-2000.
[14]尹战海,张璐,王菁.软骨寡聚基质蛋白在骨关节炎预后判断中的作用[J].陕西医学杂志,2008,37(12):1638-1640.
[15]彭成忠,肖涛.白细胞介素18和前列腺素E2与骨关节炎[J].中国组织工程研究,2006,10(16):117-120.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |